Market LIVE
Published markets; coverage varies by country
Product profile · United States

DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE

 ·  Patent Litigation & Settlement History ↓

IngredientDILTIAZEM HYDROCHLORIDE
Application typeNDA
Application218038
Product001
Dosage formSOLUTION
RouteINTRAVENOUS
Strength100MG/100ML (1MG/ML)
Approval date2025-02-21
Marketing statusPrescription
Status event—
ApplicantHQ SPCLT PHARMA
Product source

Current GenericRadar decision

Year1992
SelectionCANDIDATE
ReviewFINAL
Anchor typeREGULATORY_EXCLUSIVITY
Anchor date1992-11-05
Patent anchor—
Exclusivity anchor1992-11-05
Protection date1992-11-05
First Final ANDA—
Status event—

Candidate based on the adopted canonical anchor; no later applicable right was adopted from the reviewed sources.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
No patent facts are recorded for this product.

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
NCE1982-11-051992-11-05Historical protection covering the active ingredient. This is a reference period, not a new grant to the later NDA.YY1992-11-05—Source

2026-10-13 · HISTORICAL_RECORDS_RECOVERED · Historical coverage: ANNUALS_AND_MONTHLY_REVIEWED

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (2)
TypeDateRoleBasisSource
REGULATORY_EXCLUSIVITY1992-11-05CANONICAL_ANCHORHistorical protection covering the active ingredient. This is a reference period, not a new grant to the later NDA.Source
REGULATORY_STATUS1992-11-05CANONICAL_DECISIONCandidate based on the adopted canonical anchor; no later applicable right was adopted from the reviewed sources.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.